Moderna's stock surged by approximately 176% following positive late-stage trial results for its experimental personalized cancer vaccine, developed in partnership with Merck, aimed at preventing melanoma recurrence. The success of this trial has significantly boosted investor confidence in Moderna's future beyond its COVID-19 vaccine, although the company faces ongoing financial scrutiny and the inherent volatility of biotech stock rallies.

Moderna's stock surged by approximately 176% following positive late-stage trial results for its experimental personalized cancer vaccine, developed in partnership with Merck, aimed at preventing melanoma recurrence. The success of this trial has significantly boosted investor confidence in Moderna's future beyond its COVID-19 vaccine, although the company faces ongoing financial scrutiny and the inherent volatility of biotech stock rallies.

Moderna's stock surged by approximately 176% following positive late-stage trial results for its experimental personalized cancer vaccine, developed in partnership with Merck, aimed at preventing melanoma recurrence. The success of this trial has significantly boosted investor confidence in Moderna's future beyond its COVID-19 vaccine, although the company faces ongoing financial scrutiny and the inherent volatility of biotech stock rallies.

Moderna’s stock on NASDAQ skyrocketed by around 176 per cent after the company announced that its experimental personalised cancer vaccine showed positive results in its late-stage trial. The company has been developing the vaccine along with Merck to prevent melanoma, a form of skin cancer, from recurring in patients who have already undergone initial surgery.

The share price for the American biotechnology company jumped to $174.38 from $62.96 on 19 August, marking the company's biggest one-day gain. Merck’s share price also rose by 12.60 per cent to $152.21 from $135.17.

The Moderna’s rise to fame involved the development of the COVID-19 vaccine called Spikevax, making history with its mRNA technology. They generated $18.5 billion in total revenue for 2021, which had increased 23-fold compared to the revenue of $803 million.

However, the company’s stock tumbled by more than 80 per cent from its 2021 high as global vaccine demand slowed. This was because the company lacked a diverse portfolio, and its entire market cap rested on a temporary, emergency event.

The introduction of a new cancer vaccine has boosted investor sentiment, signalling that the company can sustain beyond the surge fuelled by COVID vaccines.

Moderna’s financials, with a Q2 net loss of $782 million, pose a problem. The Relative Strength Index (RSI) reached high levels of approximately 88 to 91 after the surge, and biotech stocks frequently fall 20 to 30 per cent in the sessions following such binary event rallies.

However, the the vaccine could be successful, giving the company a steady income.

The current market capitalisation for Moderna is $69.62 billion, and Merck has a capitalisation of approximately $333.49 billion.

What is the new vaccine?

The general treatment for Melanoma involves Merck’s Keytruda, an immunotherapy medication. It is used to treat many types of cancer, including lung, bladder and breast cancer.

The new mRNA-based shot developed by Moderna, combined with the Merck’s Keytruda, achieved important goals in a Phase 3 trial. The trial consisted of more than 1,100 patients with high-risk melanoma, whose cancer had been completely removed through surgery.

The personalised vaccine aims to trigger the body’s immune system towards the irregular cells in the tumour. This is unlike chemotherapy, which can also damage normal cells in the process.